Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

Swaika A, Hammond WA, Joseph RW.

Mol Immunol. 2015 Mar 4. pii: S0161-5890(15)00049-8. doi: 10.1016/j.molimm.2015.02.009. [Epub ahead of print] Review.

PMID:
25749122
2.

Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences.

Grotz TE, Joseph RW, Pockaj BA, Foote RL, Otley CC, Bagaria SP, Weaver AL, Jakub JW.

Ann Surg Oncol. 2015 Feb 13. [Epub ahead of print]

PMID:
25676844
3.

Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Parasramka M, Cheville JC, Wu KJ, Frenkel E, Rakheja D, Stefanius K, Brugarolas J, Parker AS.

Urol Oncol. 2015 Jan;33(1):23.e9-14. doi: 10.1016/j.urolonc.2014.10.014. Epub 2014 Nov 24.

PMID:
25465300
4.

Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.

Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, Bagaria S, Jambusaria-Pahlajani A.

Cancer Immunol Res. 2015 Jan;3(1):18-22. doi: 10.1158/2326-6066.CIR-14-0134. Epub 2014 Oct 6.

PMID:
25287118
5.

c-MET expression in primary and liver metastases in uveal melanoma.

Gardner FP, Serie DJ, Salomao DR, Wu KJ, Markovic SN, Pulido JS, Joseph RW.

Melanoma Res. 2014 Dec;24(6):617-20. doi: 10.1097/CMR.0000000000000118.

PMID:
25211165
6.

Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis.

Eckel-Passow JE, Igel DA, Serie DJ, Joseph RW, Ho TH, Cheville JC, Parker AS.

Urol Oncol. 2015 Feb;33(2):68.e17-23. doi: 10.1016/j.urolonc.2014.07.019. Epub 2014 Aug 28.

PMID:
25175426
7.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A.

Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.

8.

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.

Swaika A, Crozier JA, Joseph RW.

Drug Des Devel Ther. 2014 Jun 16;8:775-87. doi: 10.2147/DDDT.S31143. eCollection 2014.

9.

Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Joseph RW, Parasramka M, Eckel-Passow JE, Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Huu Ho T, Castle EP, Cheville J, Kwon ED, Thompson EA, Parker A.

Cancer Immunol Res. 2013 Dec;1(6):378-85. doi: 10.1158/2326-6066.CIR-13-0042. Epub 2013 Aug 29.

10.

Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass.

Starr JS, Attia S, Joseph RW, Menke D, Casler J, Smallridge RC.

J Clin Oncol. 2014 Mar 24. [Epub ahead of print] No abstract available.

PMID:
24663046
11.

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA.

Cancer Immunol Res. 2013 Dec;1(6):373-7. doi: 10.1158/2326-6066.CIR-13-0092.

12.

ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma.

Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Cheville JC, Parker AS.

BMC Urol. 2014 Jan 31;14:14. doi: 10.1186/1471-2490-14-14.

13.

Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.

Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC, Leibovich BC.

Eur Urol. 2014 Nov;66(5):929-35. doi: 10.1016/j.eururo.2013.12.017. Epub 2013 Dec 25.

PMID:
24388441
14.

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.

Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T, Cheville JC, Frenkel E, Rakheja D, Brugarolas J, Parker A.

Cancer. 2014 Apr 1;120(7):1059-67. doi: 10.1002/cncr.28521. Epub 2013 Dec 30. Erratum in: Cancer. 2014 Jun 1;120(11):1752-3.

PMID:
24382589
15.

Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma.

Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Hart SN, Cheville JC, Parker AS.

Carcinogenesis. 2014 Apr;35(4):822-7. doi: 10.1093/carcin/bgt485. Epub 2013 Dec 28.

PMID:
24374825
16.

An integrated model of the transcriptome of HER2-positive breast cancer.

Kalari KR, Necela BM, Tang X, Thompson KJ, Lau M, Eckel-Passow JE, Kachergus JM, Anderson SK, Sun Z, Baheti S, Carr JM, Baker TR, Barman P, Radisky DC, Joseph RW, McLaughlin SA, Chai HS, Camille S, Rossell D, Asmann YW, Thompson EA, Perez EA.

PLoS One. 2013 Nov 1;8(11):e79298. doi: 10.1371/journal.pone.0079298. eCollection 2013.

17.

Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies.

Parker AS, Thiel DD, Bergstralh E, Carlson RE, Rangel LJ, Joseph RW, Diehl N, Karnes RJ.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):352-6. doi: 10.1038/pcan.2013.27. Epub 2013 Aug 20.

18.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A.

N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.

19.

Age-period-cohort analysis of renal cell carcinoma in United States adults.

Tyson MD, Humphreys MR, Parker AS, Thiel DD, Joseph RW, Andrews PE, Castle EP.

Urology. 2013 Jul;82(1):43-7. doi: 10.1016/j.urology.2013.02.065. Epub 2013 May 22.

PMID:
23706585
20.

Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma.

Bagaria SP, Ray PS, Joseph RW, Heckman MG, Rawal B, Gray RJ, Pockaj B, Wasif N.

Cancer. 2013 May 15;119(10):1860-7. doi: 10.1002/cncr.27985. Epub 2013 Feb 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk